Comparing Efficacy and Safety of CTO0303 in Pediatric Subjects
Phase 2
Recruiting
- Conditions
- Pupillary Dilation Effect During Cycloplegic Refraction
- Interventions
- Drug: CTO0303-BDrug: CTO0303-CDrug: CTO0303-A
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-09-24
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 156
- Registration Number
- NCT06609525
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
Comparing Efficacy and Safety of TJO-083 in Dry Eye Diseases Patients
Phase 3
Completed
- Conditions
- Dry EyeDry Eye Syndromes
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 271
- Registration Number
- NCT06427031
- Locations
- 🇰🇷
Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of
A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy
Phase 3
Completed
- Conditions
- Bowel Preparation
- Interventions
- Drug: CTP0302-BDrug: CTP0302-ADrug: Conventional OST
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 161
- Registration Number
- NCT06287606
- Locations
- 🇰🇷
Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of
A Phase 3 Trial in Bowel Preparation for Colonoscopy
Phase 3
Completed
- Conditions
- Bowel Preparation
- Interventions
- Drug: CTP0301-BDrug: CTP0301-ADrug: Cool prep
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 137
- Registration Number
- NCT05870553
- Locations
- 🇰🇷
Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of
A Prospective, Randomized, Investigator-blinded, Parallel, Multi-center, Phase 3 Trial
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05670470
- Locations
- 🇰🇷
Kyung Hee University Hospital at Gangdong, Seoul, Gangdong, Korea, Republic of
Comparing Efficacy and Safety of TJO-083 in Dry Eye Disease Patients
Phase 1
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 98
- Registration Number
- NCT05346783
- Locations
- 🇰🇷
Hyung Keun, Lee, Seoul, Korea, Republic of
A Phase 1 Clinical Trial to Explore Systemic Exposure of CTO0101 Eye Drops, Safety and Local Tolerability in Healthy Adults
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05262179
- Locations
- 🇰🇷
Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of
Evaluating the Efficacy and Safety of TJO-087 in Moderate to Severe Dry Eye Disease Patients
Phase 3
- Conditions
- Dry Eye Syndrome
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 182
- Registration Number
- NCT05245604
- Locations
- 🇰🇷
Hyo Myung, Kim, Seoul, Korea, Republic of
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT04164459
- Locations
- 🇰🇷
Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of
Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Dry Eye Disease Patients
Phase 4
Completed
- Conditions
- Dry EyeDry Eye Syndromes
- Interventions
- Drug: TJO-018 (HA 0.15%)Drug: TJO-018 (HA 0.15%) + Cyclosporine Ophthalmic Emulsion 0.05%
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT04127851
- Locations
- 🇰🇷
Taejoon Pharmaceutical Co., Ltd., Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath